The analysis, covering clinical trials from 2002 to 2024, compared pro-angiogenic interventions against placebos across a diverse patient cohort. Results showed malignancy incidence rates of 0.84 per 100 patient-years for the treatment group, compared to 0.72 for those receiving placebos—both figures falling below the 1.0 benchmark for age-matched populations. Retinal complications were similarly rare, effectively neutralizing fears that stimulating blood vessel growth might trigger unintended pathological side effects.

This evidence provides a regulatory tailwind for Isomab’s lead candidate, ISM-001. Unlike traditional growth factor therapies that forcefully stimulate vessel production, ISM-001 functions as an antibody designed to neutralize VEGF-A165b, a protein that acts as an overactive brake on the body’s natural angiogenic processes. Chief Scientific Officer Professor David Bates described the findings as a foundation for upcoming first-in-human trials, which will target patients suffering from chronic, treatment-refractory angina. CEO Dr. Philip Brainin emphasized that the objective remains to rebalance VEGF-A signaling, allowing the heart to leverage its own capacity for self-repair rather than relying on blunt stimulation.